- Home
- BETR vs NYXH Comparison
BETR vs NYXH Comparison
Compare BETR & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BETR
- NYXH
- Stock Information
- Founded
- BETR 2014
- NYXH 2009
- Country
- BETR United States
- NYXH Belgium
- Employees
- BETR N/A
- NYXH N/A
- Industry
- BETR Finance: Consumer Services
- NYXH Medical/Dental Instruments
- Sector
- BETR Finance
- NYXH Health Care
- Exchange
- BETR Nasdaq
- NYXH Nasdaq
- Market Cap
- BETR 218.6M
- NYXH 222.3M
- IPO Year
- BETR N/A
- NYXH 2021
- Fundamental
- Price
- BETR $13.10
- NYXH $7.75
- Analyst Decision
- BETR
- NYXH Strong Buy
- Analyst Count
- BETR 0
- NYXH 4
- Target Price
- BETR N/A
- NYXH $14.50
- AVG Volume (30 Days)
- BETR 80.9K
- NYXH 76.9K
- Earning Date
- BETR 08-07-2025
- NYXH 08-05-2025
- Dividend Yield
- BETR N/A
- NYXH N/A
- EPS Growth
- BETR N/A
- NYXH N/A
- EPS
- BETR N/A
- NYXH N/A
- Revenue
- BETR $118,790,000.00
- NYXH $4,716,818.00
- Revenue This Year
- BETR N/A
- NYXH $323.07
- Revenue Next Year
- BETR N/A
- NYXH $204.30
- P/E Ratio
- BETR N/A
- NYXH N/A
- Revenue Growth
- BETR 56.38
- NYXH N/A
- 52 Week Low
- BETR $7.71
- NYXH $5.55
- 52 Week High
- BETR $30.00
- NYXH $11.87
- Technical
- Relative Strength Index (RSI)
- BETR 49.00
- NYXH 62.70
- Support Level
- BETR $13.43
- NYXH $7.45
- Resistance Level
- BETR $14.75
- NYXH $7.85
- Average True Range (ATR)
- BETR 1.01
- NYXH 0.27
- MACD
- BETR 0.12
- NYXH -0.02
- Stochastic Oscillator
- BETR 58.08
- NYXH 97.33
About BETR Better Home & Finance Holding Company
Better Home & Finance Holding Co is a digital-first homeownership company whose services include mortgage, real estate, title, and homeowners insurance. The company has combined technology innovation and fresh thinking with a deep customer focus with the goal of revolutionizing the homeownership industry.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.